<DOC>
	<DOCNO>NCT00469651</DOCNO>
	<brief_summary>This study evaluate safety candidate malaria vaccine MSP3 child age 12-24 month Tanzania highland area low malaria transmission . Written inform consent sought guardians/parents potentially participate child . Eligible child randomly allocate receive either study vaccine ( MSP3 total 30 child ) ) control vaccine ( hepatitis B total 15 child ) . The vaccine give 3 immunization one month apart study child neither clinical investigator child 's parent aware vaccine administer initial four month study . The study design begin low dose MSP3 vaccine ( 15µg MSP3 15 child ) follow high dose ( 30µg MSP3 15 child ) . Following immunization , child evaluate seven day solicit symptom . Unsolicited symptom also collect throughout study duration . The study overseen international safety monitoring committee follow safety matter closely trial progress . The study also approve Tanzania National ethic Committee , The Tanzania Food Drugs Authority , London school hygiene tropical medicine ethic committee . The study plan last 13 month participant .</brief_summary>
	<brief_title>Phase Ib Trial MSP3 LSP Children Tanzania</brief_title>
	<detailed_description>The study double blind ( observer blind , participant blind ) , randomize , control , dose escalation , Age deescalation , phase Ib study . It include two parallel group follow : - Group 1 : 23 subject ( 15 subject receive MSP3-LSP vaccine 15 µg 8 subject receive Hepatitis B vaccine ) . - Group 2 : 22 subject ( 15 subject receive MSP3-LSP vaccine 30 µg 7 subject receive Hepatitis B vaccine ) . The Immunization schedule 0 , 1 , 2 month cohort provisionally follow group : - Study day 0 , 28 56 group 1 - Study day 14 , 42 , 70 group 2 Vaccinations group 1 2 stagger : immunization group 2 start 2 week group 1 . This interval may extend deem necessary case serious adverse event safety concern . Randomization do group time first vaccination study pharmacist aware vaccine allocate particular study ID number . The pharmacist role swear confidentiality . The study vaccine administer subcutaneous injection right leave deltoid ( alternately ) . Each child observe least 60 minute vaccination evaluate treat acute adverse event . This follow Seven ( 7 ) day follow-up period solicit adverse event ( day vaccination plus 6 subsequent day ; twenty eight ( 28 ) day follow-up period unsolicited adverse event ( Vaccination day plus 27 subsequent day ) . The follow-up serious adverse event ( SAE 's ) 12 month first dose study vaccine ( 9 month dose 3 ) . Biological safety evaluate regular physical examination , blood sample routine clinical chemistry , hematology ) . At end follow-up period unsolicited AEs ( i.e. , one month third dose ) , child follow field worker home monthly interval record SAEs . There 10 clinic visit plan , however , participant advise report clinic time feel unwell . Data collection participant record file transcription conventional Case Report Forms do . All date CRFs verify clinical Monitor . The database lock study day 84 allow interim analysis review safety immunogenicity thus collect .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Children age 12 year old Healthy medical history physical examination Signed /thumb print informed Consent guardian/parent Resident study area village whole trial period Symptoms , physical sign disease could interfere interpretation trial result compromise health subject . Immunosuppressive therapy ( steroid , immune modulators immune suppressor ) within 3 month prior recruitment ( corticosteroid , mean prednisolone equivalent 0.5 mg/kg/day . Inhaled topical steroid allow ) . Can follow social , psychological geographical reason . Use investigational drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use 30 day third dose . Suspected known hypersensitivity vaccine component previous vaccine . Laboratory abnormality screen blood sample range , specifically refer table 4 . Planned administration vaccine foreseen study protocol within 30 day first dose vaccine . An exception receipt EPI license vaccine ( measles , oral polio , meningococcal combine diphtheria/pertussis/tetanus vaccine ) may give 14 day vaccination . Evidence chronic active Hepatitis B infection . Presence chronic illness , judgment investigator , would interfere study outcome pose threat participant 's health . Administration immunoglobulin and/or blood product within three month precede first dose study vaccine plan administration study period . History surgical splenectomy . Moderate severe malnutrition screening define weight age Zscore le 2</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Malaria</keyword>
	<keyword>vaccine</keyword>
	<keyword>MSP3LSP</keyword>
	<keyword>Safety</keyword>
	<keyword>child</keyword>
	<keyword>Tanzania</keyword>
</DOC>